Kostyantyn Dumchev1, Tetiana Kiriazova1, Serhiy Riabokon2, Alyona Shost3, Canada Parrish4, Anna Shapoval3, Myroslava Germanovych2, Jeremy Penner5, Jason Beste6, Nancy Puttkammer7. 1. Ukrainian Institute on Public Health Policy, Kyiv, Ukraine. 2. Public Health Center of the Ministry of Health of Ukraine, Ukraine. 3. International Training & Education Center for Health, Kyiv, Ukraine. 4. Emergency Medicine Department, University of Washington, Seattle, WA. 5. Department of Family Practice, University of British Columbia, Vancouver, British Columbia, Canada; and. 6. Departments of Medicine; and. 7. Global Health, University of Washington, Seattle, WA.
Abstract
BACKGROUND: Achievement of the UNAIDS 95-95-95 targets requires ARV regimens that are easy to use, well-tolerated, and cost-effective. Dolutegravir (DTG)-based regimens are efficacious and less costly than other common first-line regimens. This study assessed real-world effectiveness of DTG regimens in treatment-naive people living with HIV in Ukraine. METHODS: We extracted data from the national Medical Information System on all adult patients who initiated antiretroviral therapy (ART) with DTG, lopinavir/ritonavir, or efavirenz (EFV) between October 2017 and June 2018, at 23 large clinics in 12 regions of Ukraine. Viral suppression at 12 ± 3 months and retention at 12 months after treatment initiation were the outcomes of interest. RESULTS: Of total 1057 patients, 721 had a viral load test within the window of interest, and 652 (90%) had viral load of ≤ 200 copies/mL. The proportion with suppression was lower in the EFV group [aOR = 0.4 (95% confidence interval: 0.2 to 0.8)] and not different in the LPV group [aOR = 1.6 (0.5 to 4.9)] compared with the DTG group. A 24-month or longer gap between diagnosis and treatment was associated with lower odds of suppression [aOR = 0.4 (0.2 to 0.8)]. Treatment retention was 90% (957/1057), with no significant difference by regimen group. History of injecting drug use was associated with decreased retention [aOR = 0.5 (0.3 to 0.8)]. CONCLUSIONS: DTG-based regimens were comparable with LPV and more effective than EFV in achieving viral suppression among ART-naive patients in a multisite cohort in Ukraine. Treatment retention was equally high in all 3 groups. This evidence from Ukraine supports the ART Optimization Initiative as a strategy to improve efficiency of the ART program without negatively affecting patient clinical outcomes.
BACKGROUND: Achievement of the UNAIDS 95-95-95 targets requires ARV regimens that are easy to use, well-tolerated, and cost-effective. Dolutegravir (DTG)-based regimens are efficacious and less costly than other common first-line regimens. This study assessed real-world effectiveness of DTG regimens in treatment-naive people living with HIV in Ukraine. METHODS: We extracted data from the national Medical Information System on all adult patients who initiated antiretroviral therapy (ART) with DTG, lopinavir/ritonavir, or efavirenz (EFV) between October 2017 and June 2018, at 23 large clinics in 12 regions of Ukraine. Viral suppression at 12 ± 3 months and retention at 12 months after treatment initiation were the outcomes of interest. RESULTS: Of total 1057 patients, 721 had a viral load test within the window of interest, and 652 (90%) had viral load of ≤ 200 copies/mL. The proportion with suppression was lower in the EFV group [aOR = 0.4 (95% confidence interval: 0.2 to 0.8)] and not different in the LPV group [aOR = 1.6 (0.5 to 4.9)] compared with the DTG group. A 24-month or longer gap between diagnosis and treatment was associated with lower odds of suppression [aOR = 0.4 (0.2 to 0.8)]. Treatment retention was 90% (957/1057), with no significant difference by regimen group. History of injecting drug use was associated with decreased retention [aOR = 0.5 (0.3 to 0.8)]. CONCLUSIONS: DTG-based regimens were comparable with LPV and more effective than EFV in achieving viral suppression among ART-naive patients in a multisite cohort in Ukraine. Treatment retention was equally high in all 3 groups. This evidence from Ukraine supports the ART Optimization Initiative as a strategy to improve efficiency of the ART program without negatively affecting patient clinical outcomes.
Authors: Andrew N Phillips; Francois Venter; Diane Havlir; Anton Pozniak; Daniel Kuritzkes; Annemarie Wensing; Jens D Lundgren; Andrea De Luca; Deenan Pillay; John Mellors; Valentina Cambiano; Loveleen Bansi-Matharu; Fumiyo Nakagawa; Thokozani Kalua; Andreas Jahn; Tsitsi Apollo; Owen Mugurungi; Polly Clayden; Ravindra K Gupta; Ruanne Barnabas; Paul Revill; Jennifer Cohn; Silvia Bertagnolio; Alexandra Calmy Journal: Lancet HIV Date: 2018-11-29 Impact factor: 12.767
Authors: Steve Kanters; Marco Vitoria; Meg Doherty; Maria Eugenia Socias; Nathan Ford; Jamie I Forrest; Evan Popoff; Nick Bansback; Sabin Nsanzimana; Kristian Thorlund; Edward J Mills Journal: Lancet HIV Date: 2016-09-06 Impact factor: 12.767
Authors: Ingrid T Katz; Annemarie E Ryu; Afiachukwu G Onuegbu; Christina Psaros; Sheri D Weiser; David R Bangsberg; Alexander C Tsai Journal: J Int AIDS Soc Date: 2013-11-13 Impact factor: 5.396
Authors: Andrea J Low; Gitau Mburu; Nicky J Welton; Margaret T May; Charlotte F Davies; Clare French; Katy M Turner; Katharine J Looker; Hannah Christensen; Susie McLean; Tim Rhodes; Lucy Platt; Matthew Hickman; Andy Guise; Peter Vickerman Journal: Clin Infect Dis Date: 2016-06-25 Impact factor: 9.079